Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naoshuantong Capsule for prevention of early recurrence after acute ischemic stroke
ChiCTR2300075877Phase 4Completed
- Sponsor
- First Affiliated Hospital of Henan University of Chinese Medicine
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of naoshuantong in ischemic stroke (2 arms), sponsored by First Affiliated Hospital of Henan University of Chinese Medicine. Primary endpoint: New stroke events within 90 days of onset. Started Dec 2022; status: completed.
02
Drugs
naoshuantong
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2300075877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075877.